Differential growth inhibition, cell cycle arrest and apoptosis of MCF-7 and MDA-MB-231 cells to holocarboxylase synthetase suppression
Issued Date
2022-02-19
Resource Type
ISSN
0006291X
eISSN
10902104
Scopus ID
2-s2.0-85123079149
Pubmed ID
35063765
Journal Title
Biochemical and Biophysical Research Communications
Volume
593
Start Page
108
End Page
115
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biochemical and Biophysical Research Communications Vol.593 (2022) , 108-115
Suggested Citation
Siritutsoontorn S., Sukjoi W., Polyak S.W., Akekawatchai C., Jitrapakdee S. Differential growth inhibition, cell cycle arrest and apoptosis of MCF-7 and MDA-MB-231 cells to holocarboxylase synthetase suppression. Biochemical and Biophysical Research Communications Vol.593 (2022) , 108-115. 115. doi:10.1016/j.bbrc.2022.01.049 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83820
Title
Differential growth inhibition, cell cycle arrest and apoptosis of MCF-7 and MDA-MB-231 cells to holocarboxylase synthetase suppression
Author's Affiliation
Other Contributor(s)
Abstract
Holocarboxylase synthetase (HLCS) catalyzes the covalent attachment of biotin onto the biotin-dependent carboxylases. Recent studies have shown that HLCS is over-expressed in breast cancer patients. Here we investigated the functional roles of free biotin and HLCS in supporting growth and migration of breast cancer cell lines. Depletion of biotin from culture medium markedly reduced biotinylation of the two most abundant biotin-carboxylases, acetyl-CoA carboxylase and pyruvate carboxylase. This was accompanied by a marked decrease in cell growth. Suppression of HLCS expression in the low invasive breast cancer cell line MCF-7 resulted in an 80% reduction of biotinylated ACC, but not PC. HLCS knockdown MCF-7 cell lines showed 40-50% reduction of proliferation and 35% reduction of migration, accompanied by G1 cell cycle-arrest-induced apoptosis. In contrast, knockdown of HLCS expression in the highly invasive cell line MDA-MB-231 resulted in only marginal reduction of biotinylation of both ACC and PC, accompanied by 30% reduction of proliferation and 30% reduction of migration. Our studies provide new insights to use HLCS as a novel anti-cancer drug target.